Elebsiran, a novel small interfering RNA (siRNA) targeting HBV transcripts, significantly enhances hepatitis B surface antigen (HBsAg) loss when combined with pegylated interferon alfa (PEG-IFNα) in chronic HBV patients.
Randomized phase 2 trials show HBsAg loss rates up to 33.3% with elebsiran plus PEG-IFNα, substantially higher than PEG-IFNα monotherapy alone.
The HBV therapeutic vaccine BRII-179 demonstrates potential for immunological profiling, identifying anti-HBs responders who achieve higher functional cure rates with combination therapy.
Safety profiles for elebsiran plus PEG-IFNα are favorable, with mostly mild to moderate adverse events and manageable alanine aminotransferase elevations.
